514LBA (PB-514) LBA Posters: Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
Titel:
514LBA (PB-514) LBA Posters: Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
Auteur:
Wolpin, B. Hong, D. Spira, A. Starodub, A. Park, W. Sommerhalder, D. Valerin, J. Barve, M. Punekar, S. Pelster, M. Herzberg, B. Azad, N. Aung, K. Hecht, J.R. Cheng, L. Vora, R. Salman, Z. Zhang, Y. Lin, T. Garrido-Laguna, I.